Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock

  Anthera Pharmaceuticals Announces Completion of Public Offering of Common

PR Newswire

HAYWARD, Calif., Jan. 30, 2013

HAYWARD, Calif., Jan. 30, 2013 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH) today announced that it has completed the previously announced
underwritten public offering of 60,606,061 shares of its common stock, offered
at a price of $0.66 per share. In addition, Anthera has granted the
underwriters a 30-day option to purchase up to an additional 9,090,909
shares. The gross proceeds to the Company from the sale of shares in this
offering, before deducting customary underwriting discounts and commissions,
were $40.0 million. Anthera intends to use the net proceeds from this
offering for general corporate purposes.

Jefferies & Company, Inc. is acting as sole book-running manager in the
offering and Leerink Swann LLC is acting as co-manager. Trout Capital LLC has
acted as an advisor to the Company.

The securities described above were offered by the Company pursuant to a shelf
registration statement previously filed with, and declared effective by, the
Securities and Exchange Commission (the "SEC"). A final prospectus supplement
and accompanying prospectus relating to the offering has been filed with the
SEC and is available on the SEC's website at Copies of
the final prospectus supplement and the accompanying prospectus relating to
this offering may be obtained from Jefferies & Company, Inc., Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New
York, NY 10022, or by telephone at 877-547-6340, or by email at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of any such state or jurisdiction.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement
Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include statements about the Company's expectations with respect to
its public offering, including statements about its intended use of proceeds
from the offering. Such statements are based on the Company's expectations as
of the date of this press release and are subject to certain risks and
uncertainties that could cause actual results to differ materially, including
but not limited to those set forth in the Company's public filings with the
SEC, including the Company's Annual Report on Form 10-K for the year ended
December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2012. The Company disclaims any intent or obligation to update
any forward-looking statements, whether because of new information, future
events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., or

SOURCE Anthera Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.